<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610645</url>
  </required_header>
  <id_info>
    <org_study_id>EKS 39/18</org_study_id>
    <nct_id>NCT04610645</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography in Patients With Radiotherapy for Head and Neck Cancer</brief_title>
  <acronym>ROOCT</acronym>
  <official_title>Live Laser Microscopic Evaluation (OCT) of Radiation Induced Preclinical Alterations of the Skin in Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verein zur Forschungsförderung der Krebshilfe OÖ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RECENDT GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Kepler Universität Linz, Abteilung FLLL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Krankenhaus Barmherzige Schwestern Linz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether any eventual skin damage caused by&#xD;
      radiation therapy can be detected and monitored at a subclinical level via optical coherence&#xD;
      tomography (OCT). Another key question is whether subclinical OCT detected skin damage&#xD;
      correlates with acute and late clinical toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Head and neck cancer patients that meet the eligibility criteria and singned the informed&#xD;
      consent will undergo OCT-measurements before, during and after the course of radiation&#xD;
      therapy. At the same time-points the skin areas are evaluated with dermatoscopy and patients&#xD;
      are asked to self-assess their quality of life (EORTC QLQ C30 and respective head and neck&#xD;
      module H&amp;N 43). Before the onset of radiation therapy radiation sensitivity analysis will be&#xD;
      performed with in-vitro irradion of peripheral blood lymphocytes (FISH).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 8, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>early radiation induced skin structure changes detected in OCT</measure>
    <time_frame>First week of radiation therapy</time_frame>
    <description>any reproducible difference in skin OCT appearance as compared with baseline (pre-RT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>detection of any skin strucure changes with OCT during the course of RT</measure>
    <time_frame>weeks 1 - 6 of radiation therapy</time_frame>
    <description>any reproducible difference in skin OCT appearance as compared with baseline (pre-RT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of OCT changes with clinical appearent acute side effetcs</measure>
    <time_frame>weeks 1 - 6 of radiation therapy</time_frame>
    <description>Correlation of OCT changes with CTC radiation toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of OCT changes with clinical appearent late side effetcs</measure>
    <time_frame>1 year post-RT</time_frame>
    <description>Correlation of OCT changes with CTC radiation toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of OCT changes with radiation sensitivity</measure>
    <time_frame>OCT: weeks 1-6 of radiation therapy; FISH: pre-RT</time_frame>
    <description>Correlation of OCT with chromosome-breaks per metaphasis in in-vitro irradiated blood lymphocytes (FISH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of OCT changes with dermatoscopic skin appearance</measure>
    <time_frame>weeks 1-6 of RT</time_frame>
    <description>Correlation of OCT changes with standardised evaluated skin appearence via dermatoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of quality of live with OCT and radiation sensitivity</measure>
    <time_frame>weeks 1-6 of RT, 6 weeks and 1 year post-RT</time_frame>
    <description>Correlation of quality of live as measured with the EORT QLC C30 and Head and neck module H&amp;N 43 with OCT and radiation sensitivity</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Head and Neck Cancer Patients</arm_group_label>
    <description>Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck</description>
    <arm_group_label>Head and Neck Cancer Patients</arm_group_label>
    <other_name>Lumedica OQlabscope 2.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermatoscope</intervention_name>
    <description>2x2 pictures taken with a dermatoscope</description>
    <arm_group_label>Head and Neck Cancer Patients</arm_group_label>
    <other_name>Heine iC1 Set/6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>3-Colour FISH</intervention_name>
    <description>Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual</description>
    <arm_group_label>Head and Neck Cancer Patients</arm_group_label>
    <other_name>Fluorescent In Situ Hybridisation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutively treated patients with head and neck cancer at the department of radiation&#xD;
        therapy Ordensklinikum Linz Barmherzige Schwestern&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cancer located at: nasopharynx, oropharynx, hypopharynx, larynx, oral&#xD;
             cavity and definitive or adjuvant radiation- or radio-chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  reduced mental capacity&#xD;
&#xD;
          -  treatment with C225 Cetuximab&#xD;
&#xD;
          -  bearded patients&#xD;
&#xD;
          -  overt skin disease&#xD;
&#xD;
          -  vast tattoos in the neck region&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Geinitz, Prim. Univ.-Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ordensklinikum Linz GmbH Barmherzige Schwestern (Dept. Radiooncology)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Silberberger, MSc</last_name>
    <phone>+43 (732) 7677</phone>
    <phone_ext>6484</phone_ext>
    <email>elisabeth.silberberger@ordensklinikum.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Geinitz, Prim. Univ.-Prof. Dr.</last_name>
    <phone>+43 (732) 7677</phone>
    <phone_ext>6938</phone_ext>
    <email>hans.geinitz@ordensklinikum.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiooncology, Ordensklinikum Linz GmbH Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Silberberger, MSC</last_name>
      <phone>+43 (732) 7677</phone>
      <phone_ext>6484</phone_ext>
      <email>elisabeth.silberberger@ordensklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Hans Geinitz, Prim. Univ.-Prof. Dr.</last_name>
      <phone>+43 (732) 7677</phone>
      <phone_ext>6938</phone_ext>
      <email>hans.geinitz@ordensklinikum.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Krankenhaus Barmherzige Schwestern Linz</investigator_affiliation>
    <investigator_full_name>Hans Geinitz</investigator_full_name>
    <investigator_title>Prim. Univ.-Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Optical coherence tomography</keyword>
  <keyword>OCT</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>skin toxicity</keyword>
  <keyword>radiation sensitivity</keyword>
  <keyword>FISH</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>EORTC QLQ C30</keyword>
  <keyword>EORTC H&amp;N 43</keyword>
  <keyword>Radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

